Shots:
- Formation Bio reported that its subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi, which will investigate it in a new, previously unstudied indication through a P-I trial
- The deal could total up to €545M ($627.64M), including upfront and milestone payments, along with low to mid-teen royalties on future sales
- Formation Bio acquired Gusacitinib in late 2022 from Asana BioSciences. The Sanofi deal marks its next development phase, with Sanofi applying its global expertise to explore new indications
Ref: PRNewsWire| Image: Formation Bio and Sanofi| Press Release
Related News:- Royalty Pharma Purchases Revolution Medicines’ Royalty Rights of Daraxonrasib for ~2B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
